Matthias Kant

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

Raju Kapoor, Pei‐Ran Ho, Nolan Campbell et al. · The Lancet Neurology · 2018 · 337 citations · Full text

Life Sciences, Neurology, Pharmacotherapy +14

Treatment Escalation vs Immediate Initiation of Highly Effective Treatment for Patients With Relapsing-Remitting Multiple Sclerosis

Tim Spelman, Melinda Magyari, Fredrik Piehl et al. · JAMA Neurology · 2021 · 234 citations · Full text

Education, Neurology, Disability Management +13

Initial high-efficacy disease-modifying therapy in multiple sclerosis

Mathias Due Buron, Thor Ameri Chalmer, Finn Sellebjerg et al. · Neurology · 2020 · 159 citations

Medicine, Neurology, Comparative Effectiveness Research +13

Nationwide prevalence and incidence study of neuromyelitis optica spectrum disorder in Denmark

Viktoria Papp, Zsolt Illés, Melinda Magyari et al. · Neurology · 2018 · 104 citations · Full text

Medicine, Neurology, Neuro-ophthalmology +14

Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis

Izanne Roos, Stella Hughes, Gavin McDonnell et al. · JAMA Neurology · 2023 · 60 citations · Full text

Pharmacy, Neurology, Pharmacotherapy +15